Cargando…

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors

Background: Immune-related adverse events (irAEs) are side effects that reflect the activation of patients’ immune systems after treatment with immune checkpoint inhibitors (ICIs). However, there is no meta-analysis on the effect of early irAEs on patient survival. Thus, we assessed the association...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, You-Cheng, Zhu, Tian-Chen, Nie, Run-Cong, Lu, Liang-He, Xiang, Zhi-Cheng, Xie, Dan, Luo, Rong-Zhen, Cai, Mu-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917734/ https://www.ncbi.nlm.nih.gov/pubmed/36769385 http://dx.doi.org/10.3390/jcm12030736

Ejemplares similares

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors
por: Yoon, Jee Hee, et al.
Publicado: (2021)

Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis
por: Zhao, Fangmin, et al.
Publicado: (2022)

Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
por: Zhou, Yanting, et al.
Publicado: (2023)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors
por: Griewing, Luisa Maria, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Recent Findings in the Posttranslational Modifications of PD-L1
por: Li, Shu-Man, et al.
Publicado: (2020)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2021)

The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
por: Nie, Run-Cong, et al.
Publicado: (2020)

Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD‐1/PD‐L1 inhibitors
por: Kang, Da Hyun, et al.
Publicado: (2018)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
por: Kapoor, Akhil, et al.
Publicado: (2022)

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma
por: Zhao, Jing-Jing, et al.
Publicado: (2020)

Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
por: Eun, Yeonghee, et al.
Publicado: (2019)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Zhang, Yixi, et al.
Publicado: (2022)

The Inconsistent and Inadequate Reporting Of Immune‐Related Adverse Events in PD‐1/PD‐L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials
por: Xie, Tong, et al.
Publicado: (2021)

Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis
por: Nie, Run-Cong, et al.
Publicado: (2021)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
por: Zubiri, Leyre, et al.
Publicado: (2019)

Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
por: Baxi, Shrujal, et al.
Publicado: (2018)

Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models
por: Kim, Woorim, et al.
Publicado: (2021)

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors
por: Chen, Jianing, et al.
Publicado: (2022)

A real-world retrospective study of incidence and associated factors of endocrine adverse events related to PD-1/PD-L1 inhibitors
por: Wang, Zhiyi, et al.
Publicado: (2023)

C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients
por: Zhang, Yiyang, et al.
Publicado: (2022)

Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
por: Chen, Xiao-Jiang, et al.
Publicado: (2023)

Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses
por: Li, Jing, et al.
Publicado: (2019)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
por: Wu, Chiao-En, et al.
Publicado: (2020)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Xie, Peiyi, et al.
Publicado: (2021)

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach
por: Grimaud, Fabien, et al.
Publicado: (2021)

OR28-07 Increased BMI Is Associated With Anti PD-1/PD-L1-Induced Thyroid Immune-Related Adverse Events
por: Pollack, Rena, et al.
Publicado: (2020)

Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice
por: Sabaté Gallego, Mònica, et al.
Publicado: (2022)

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China
por: Chen, Xiaoling, et al.
Publicado: (2021)

Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
por: Rubino, Rossella, et al.
Publicado: (2021)

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction
por: Lu, Chih-Hao, et al.
Publicado: (2022)

Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis
por: Zhang, Qian, et al.
Publicado: (2021)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events
por: Mohammed, Nader, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v2co6bime1ukddmpitia6ec2v6